Follow-up studies on preterm infants after maternal beta-receptor agonist treatment.
A review of the existing literature regarding the outcome of infants delivered preterm after antenatal beta-receptor agonist treatment of the mother is presented. Some investigators have reported an increased rate of neonatal and long-term hazards, while others have not found a higher incidence of such complications after antenatal beta-receptor treatment. In our own material of 55 preterm survivors with follow-up up to 2 years of age, we found a modest rise in postnatal hypoglycemia rate but no other short-term or long-term sequelae. Postnatal monitoring of blood glucose and cardiovascular function is warranted at preterm deliveries after antenatal beta-receptor agonist treatment.
D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000139:chemically induced*; D008431:Maternal-Fetal Exchange; D007752:Obstetric Labor, Premature / Q000517:prevention & control; D011247:Pregnancy; D013726:Terbutaline / Q000009:adverse effects*
D013726:Terbutaline